World Journal of Urology

, Volume 26, Issue 1, pp 13–18 | Cite as

Screening for bladder cancer: a perspective

Topic Paper

Abstract

Bladder cancer is the seventh most common cancer worldwide in men and the 17th in women with an overall number of 356,000 new cases of urinary bladder cancer worldwide in 2002. It is one of the most expensive cancers from diagnosis to death and the fifth most expensive cancer in terms of total medical care expenditures in the US. A screening program that resulted in detection of bladder cancer at an earlier stage, prior to muscle invasion or metastasis, could render a significant improvement in patient morbidity and overall survival. Acceptance of wide-spread screening strategies requires careful consideration of the competing risks, benefits, and costs associated with such policies. In this article, we will review the pros and cons of bladder cancer screening with a focus on cost-effectiveness and who should be screened.

Keywords

Bladder cancer screening Cost-effectiveness Target population 

Notes

Acknowledgments

Conflict of Interest

Yair Lotan is an independent investigator performing a bladder cancer screening study supported by Matritech, Inc.

References

  1. 1.
    Britton JP, Dowell AC, Whelan P, Harris CM (1992) A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 148(3):788–790PubMedGoogle Scholar
  2. 2.
    Messing EM, Young TB, Hunt VB, Newton MA, Bram LL, Vaillancourt A, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD (1995) Hematuria home screening: repeat testing results. J Urol 154(1):57–61PubMedCrossRefGoogle Scholar
  3. 3.
    NCI (2007) “NCI cancer screening overview.” http://www.cancer.gov/cancerinfo/pdq/screening/overview. Accessed 26 Aug 2007
  4. 4.
    Beinfeld MT, Wittenberg E, Gazelle GS (2005) Cost-effectiveness of whole-body CT screening. Radiology 234(2):415–422PubMedCrossRefGoogle Scholar
  5. 5.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRefGoogle Scholar
  6. 6.
    Silverman DT, Hartge P, Morrison AS, Devesa SS (1992) Epidemiology of bladder cancer. Hematol Oncol Clin North Am 6(1):1–30PubMedGoogle Scholar
  7. 7.
    Zeegers MP, Tan FE, Dorant E, van den Brandt PA (2000) The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89(3):630–639PubMedCrossRefGoogle Scholar
  8. 8.
    Samanic C, Kogevinas M, Dosemeci M, Malats N, Real FX, Garcia-Closas M, Serra C, Carrato A, Garcia-Closas R, Sala M et al (2006) Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev 15(7):1348–1354PubMedCrossRefGoogle Scholar
  9. 9.
    Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardon A, Serra C, Carrato A, Garcia-Closas R et al (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish bladder cancer study and meta-analyses. Lancet 366(9486):649–659PubMedCrossRefGoogle Scholar
  10. 10.
    Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5(9):713–725PubMedCrossRefGoogle Scholar
  11. 11.
    Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21(18):1315–1330PubMedCrossRefGoogle Scholar
  12. 12.
    American College of Surgeons. Commission on Cancer National Cancer Database. http://www.facs.org/cancer/ncdb/index.html. Accessed 7 Sep 2005
  13. 13.
    Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) SEER*Stat Database: Incidence––SEER 9 Regs Public-Use, Nov 2004 Sub (1973–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission
  14. 14.
    Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19(3):666–675PubMedGoogle Scholar
  15. 15.
    Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23(27):6533–6539PubMedCrossRefGoogle Scholar
  16. 16.
    Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Bram LL, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD (1995) Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45(3):387–396 discussion 396–397PubMedCrossRefGoogle Scholar
  17. 17.
    Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, Wegenke JD, Stephenson L, Gee J, Feng C (2006) Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107(9):2173–2179PubMedCrossRefGoogle Scholar
  18. 18.
    Mayfield MP, Whelan P (1998) Bladder tumours detected on screening: results at 7 years. Br J Urol 82(6):825–828PubMedGoogle Scholar
  19. 19.
    Rodgers M, Nixon J, Hempel S, Aho T, Kelly J, Neal D, Duffy S, Ritchie G, Kleijnen J, Westwood M. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess 10(18):iii-iv, xi-259PubMedGoogle Scholar
  20. 20.
    Lotan Y, Roehrborn CG (2003) Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61(1):109–118PubMedCrossRefGoogle Scholar
  21. 21.
    Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO, Jansz K, Bridge JA, Johansson SL, Persons DL et al (2006) Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 176(1):44–47PubMedCrossRefGoogle Scholar
  22. 22.
    Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y (2005) Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293(7):810–816PubMedCrossRefGoogle Scholar
  23. 23.
    Benoit RM, Gronberg H, Naslund MJ (2001) A quantitative analysis of the costs and benefits of prostate cancer screening. Prostate Cancer Prostatic Dis 4(3):138–145PubMedCrossRefGoogle Scholar
  24. 24.
    Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN (2002) Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. preventive services task force. Ann Intern Med 137(2):132–141PubMedGoogle Scholar
  25. 25.
    Redaelli A, Cranor CW, Okano GJ, Reese PR (2003) Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics 21(17):1213–1238PubMedCrossRefGoogle Scholar
  26. 26.
    Lindfors KK, Rosenquist CJ (1995) The cost-effectiveness of mammographic screening strategies. JAMA 274(11):881–884PubMedCrossRefGoogle Scholar
  27. 27.
    Shen Y, Parmigiani G (2005) A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations. Cancer Epidemiol Biomarkers Prev 14(2):529–532PubMedCrossRefGoogle Scholar
  28. 28.
    Peto J, Gilham C, Fletcher O, Matthews FE (2004) The cervical cancer epidemic that screening has prevented in the UK. Lancet 364(9430):249–256PubMedCrossRefGoogle Scholar
  29. 29.
    Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, Willan AR, Ernst S, Moore MJ, Neville A et al (1998) Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol 16(6):2272–2279PubMedGoogle Scholar
  30. 30.
    Krahn MD, Coombs A, Levy IG (1999) Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen. CMAJ 160(1):49–57PubMedGoogle Scholar
  31. 31.
    Lotan Y, Svatek RS, Sagalowsky AI (2006) Should we screen for bladder cancer in a high-risk population?: a cost per life-year saved analysis. Cancer 107(5):982–990PubMedCrossRefGoogle Scholar
  32. 32.
    Svatek RS, Sagalowsky AI, Lotan Y (2006) Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol 24(4):338–343PubMedGoogle Scholar
  33. 33.
    Mehlman MJ (2004) Predictive genetic testing in urology: ethical and social issues. World J Urol 21(6):433–437PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of UrologyThe University of Texas Southwestern Medical CenterDallasUSA
  2. 2.Department Urologic OncologyMD Anderson Cancer CenterHoustonUSA
  3. 3.Cancer Epidemiology GroupCentro Nacional de Investigaciones OncológicasMadridSpain

Personalised recommendations